Hundreds of people with a rare and aggressive form of leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after it was recommended for routine commissioning by the NHS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback